Search Results - "AKEWANLOP, Charuwan"

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer by Wu, Yi-Long, Tsuboi, Masahiro, He, Jie, John, Thomas, Grohe, Christian, Majem, Margarita, Goldman, Jonathan W, Laktionov, Konstantin, Kim, Sang-We, Kato, Terufumi, Vu, Huu-Vinh, Lu, Shun, Lee, Kye-Young, Akewanlop, Charuwan, Yu, Chong-Jen, de Marinis, Filippo, Bonanno, Laura, Domine, Manuel, Shepherd, Frances A, Zeng, Lingmin, Hodge, Rachel, Atasoy, Ajlan, Rukazenkov, Yuri, Herbst, Roy S

“…The incidence of recurrence after curative resection among patients with stage IB, II, or IIIA non–small-cell lung cancer is high and is only slightly lower…”
Get full text

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC by Wu, Yi-Long, John, Thomas, Grohe, Christian, Majem, Margarita, Goldman, Jonathan W, Kim, Sang-We, Kato, Terufumi, Laktionov, Konstantin, Vu, Huu Vinh, Wang, Zhijie, Lu, Shun, Lee, Kye Young, Akewanlop, Charuwan, Yu, Chong-Jen, de Marinis, Filippo, Bonanno, Laura, Domine, Manuel, Shepherd, Frances A, Zeng, Lingmin, Atasoy, Ajlan, Herbst, Roy S, Tsuboi, Masahiro

“…Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3…”
Get more information

Favorable outcome of immunotherapy in a rare subtype of hepatocellular carcinoma: a case report and literature review by Archwamety, Anita, Kunapinun, Nique, Sirinvaravong, Sirinart, Apisarnthanarak, Piyaporn, Akewanlop, Charuwan, Korphaisarn, Krittiya

“…Scirrhous hepatocellular carcinoma (S-HCC) represents an uncommon subtype of HCC. During radiological evaluation this unique subtype is frequently mistaken as…”
Get full text

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand by Dajsakdipon, Thanate, Susiriwatananont, Thiti, Wongkraisri, Concord, Ithimakin, Suthinee, Parinyanitikul, Napa, Supavavej, Archara, Dechaphunkul, Arunee, Sunpaweravong, Patrapim, Neesanun, Sunee, Akewanlop, Charuwan, Dejthevaporn, Thitiya

“…The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 -) advanced breast cancer…”
Get full text

Primary pulmonary lymphoepithelioma‐like carcinoma treated with immunotherapy: A case report and literature review by Archwamety, Anita, Ruangchira‐urai, Ruchira, Akewanlop, Charuwan, Korphaisarn, Krittiya

“…Here, we report a case of metastatic Epstein–Barr virus (EBV)‐related primary pulmonary lymphoepithelioma‐like carcinoma (PPLELC) in a young, nonsmoking female…”
Get full text

Low Fat-Free Mass Index Measured by Bioelectrical Impedance Analysis Correlates With Hematologic Adverse Events in Early-Stage Breast Cancer Patients Receiving Chemotherapy: A Prospective Observational Cohort Study by Thanestada, Jirawat, Srinonprasert, Varalak, Nimmannit, Akarin, Korphaisarn, Krittiya, Pramyothin, Pornpoj, Akewanlop, Charuwan

“…Background: Low muscle mass is associated with worse cancer treatment outcomes. Although dual-energy X-ray absorptiometry or computerized tomography-based…”
Get full text

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer by Rugo, Hope S., Pennella, Eduardo J., Gopalakrishnan, Unmesh, Hernandez-Bronchud, Miguel, Herson, Jay, Koch, Hans Friedrich, Loganathan, Subramanian, Deodhar, Sarika, Marwah, Ashwani, Manikhas, Alexey, Bondarenko, Igor, Mukhametshina, Guzel, Nemsadze, Gia, Parra, Joseph D., Abesamis-Tiambeng, Maria Luisa T., Baramidze, Kakhaber, Akewanlop, Charuwan, Vynnychenko, Ihor, Sriuranpong, Virote, Mamillapalli, Gopichand, Roy, Sirshendu, Yanez Ruiz, Eduardo Patricio, Barve, Abhijit, Fuentes-Alburo, Adolfo, Waller, Cornelius F.

“…Purpose The phase 3 HERITAGE trial demonstrated that the biosimilar trastuzumab-dkst is well tolerated with similar efficacy (measured by overall response rate…”
Get full text

Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study by Archwamety, Anita, Teeyapun, Nattaya, Siripoon, Teerada, Poungvarin, Naravat, Tanasanvimon, Suebpong, Sirachainan, Ekaphop, Akewanlop, Charuwan, Korphaisarn, Krittiya

“…Current guidelines recommend anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR Ab) as first-line treatment only in patients with…”
Get full text

Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer by Korphaisarn, Krittiya, Pongpaibul, Ananya, Limwongse, Chanin, Roothumnong, Ekkapong, Klaisuban, Wipawi, Nimmannit, Akarin, Jinawath, Artit, Akewanlop, Charuwan

“…AIM:To determine the prognostic significance of deficient mismatch repair(d MMR) and BRAF V600 E in Thai sporadic colorectal cancer(CRC) patients.METHODS:We…”
Get full text

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial by Rugo, Hope S., Pennella, Eduardo J., Gopalakrishnan, Unmesh, Hernandez-Bronchud, Miguel, Herson, Jay, Koch, Hans Friedrich, Loganathan, Subramanian, Deodhar, Sarika, Marwah, Ashwani, Manikhas, Alexey, Bondarenko, Igor, Parra, Joseph D., Abesamis-Tiambeng, Maria Luisa T., Akewanlop, Charuwan, Vynnychenko, Ihor, Sriuranpong, Virote, Roy, Sirshendu, Yanez Ruiz, Eduardo Patricio, Barve, Abhijit, Waller, Cornelius F.

“…Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or…”
Get full text

Breast Cancer Subtypes Identified by the ER, PR and HER-2 Status in Thai Women by Chuthapisith, Suebwong, Permsapaya, Watthanasak, Warnnissorn, Malee, Akewanlop, Charuwan, Sirivatanauksorn, Vorapan, Osoth, Poramaporn Prasarttong

“…Expression of estrogen-receptor (ER), progesterone-receptor (PR) and HER-2 has recently been linked with various breast cancer subtypes identified by gene…”
Get full text

The effect of primary tumor location on second- or later-line treatment with anti-EGFR antibodies in patients with metastatic colorectal cancer: A single-center cohort study by Archwamety, Anita, Poungvarin, Naravat, Akewanlop, Charuwan, Korphaisarn, Krittiya

“…Abstract only 3541 Background: The guideline recommends anti-EGFR monoclonal antibodies (anti-EGFR Ab) as first-line treatment only for patients with…”
Get full text

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial by Herbst, Roy S, Wu, Yi-Long, John, Thomas, Grohe, Christian, Majem, Margarita, Wang, Jie, Kato, Terufumi, Goldman, Jonathan W, Laktionov, Konstantin, Kim, Sang-We, Yu, Chong-Jen, Vu, Huu Vinh, Lu, Shun, Lee, Kye Young, Mukhametshina, Guzel, Akewanlop, Charuwan, de Marinis, Filippo, Bonanno, Laura, Domine, Manuel, Shepherd, Frances A, Urban, Damien, Huang, Xiangning, Bolanos, Ana, Stachowiak, Marta, Tsuboi, Masahiro

“…The phase III ADAURA (ClinicalTrials.gov identifier: NCT02511106) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit…”
Get full text

Genomic alteration in sporadic adolescent and young adult-onset colorectal adenocarcinoma by Korphaisarn, Krittiya, Sakornsakolpat, Phuwanat, Pongpaibul, Ananya, Roothumnong, Ekkapong, Thongnoppakhun, Wanna, Akewanlop, Charuwan, Pithukpakorn, Manop

“…154 Background: Colorectal cancer (CRC) incidence is increasing in adults younger than 50 years. This study evaluated genomic alteration in adolescent and…”
Get full text

Effect of primary tumor location on second- or later-line treatment with anti-epidermal growth factor receptor antibodies in patients with metastatic colorectal cancer: A retrospective multicenter study by Korphaisarn, Krittiya, Archwamety, Anita, Sintawichai, Nattaya, Siripoon, Teerada, Poungvarin, Naravat, Tanasanvimon, Suebpong, Sirachainan, Ekaphop, Akewanlop, Charuwan

“…Abstract only 195 Background: Currently, there are no guideline recommendations of anti-EGFR Ab specific to tumor sidedness in subsequent-line treatment in…”
Get full text

Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy by Ithimakin, Suthinee, Theeratrakul, Pathra, Laocharoenkiat, Apirom, Nimmannit, Akarin, Akewanlop, Charuwan, Soparattanapaisarn, Nopadol, Techawattanawanna, Sirisopa, Korphaisarn, Krittiya, Danchaivijitr, Pongwut

“…Purpose We assessed the efficacy of aprepitant (APR) or 10 or 5 mg OLN (OLN10 or OLN5) plus ondansetron and dexamethasone for chemotherapy-induced…”
Get full text

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer: A Randomized Clinical Trial by Rugo, Hope S, Barve, Abhijit, Waller, Cornelius F, Hernandez-Bronchud, Miguel, Herson, Jay, Yuan, Jinyu, Sharma, Rajiv, Baczkowski, Mark, Kothekar, Mudgal, Loganathan, Subramanian, Manikhas, Alexey, Bondarenko, Igor, Mukhametshina, Guzel, Nemsadze, Gia, Parra, Joseph D, Abesamis-Tiambeng, Maria Luisa T, Baramidze, Kakhaber, Akewanlop, Charuwan, Vynnychenko, Ihor, Sriuranpong, Virote, Mamillapalli, Gopichand, Ray, Sirshendu, Yanez Ruiz, Eduardo P, Pennella, Eduardo

“…IMPORTANCE: Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy significantly improves outcome in patients with ERBB2…”
Get full text

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer by Dechaphunkul, Arunee, Neesanun, Sunee, Parinyanitikul, Napa, Susiriwatananont, Thiti, Dajsakdipon, Thanate, Wongkraisri, Concord, Akewanlop, Charuwan, Ithimakin, Suthinee, Sunpaweravong, Patrapim, Dejthevaporn, Thitiya, Supavavej, Archara

“…Background The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 -) advanced…”
Get full text

Loss of CDX‐2 expression is an independent poor prognostic biomarker in patients with early‐stage deficient mismatch repair colorectal cancer by Korphaisarn, Krittiya, Sukhokanjanachusak, Kanjana, Pongpaibul, Ananya, Chinswangwatanakul, Vitoon, Akewanlop, Charuwan

“…Aim To investigate the clinicopathological factors, molecular features, and prognostic implications associated with loss of Caudal‐related homeobox…”
Get full text

Clinical impact of the rapid genomic screening platform for non-small cell lung cancer in Asia-Pacific (LC-SCRUM-AP) by Umemura, Shigeki, Kuo, Chih-Hsi, Sriuranpong, Virote, Thiagarajan, Muthukkumaran, Akewanlop, Charuwan, Murata, Yuri, Shibata, Yuji, Prae, Methaneethorn, Ikeda, Tatsuya, Egami, Kaori, Chase, Genevieve, Svedman, Christer, Seto, Takashi, Izumi, Hiroki, Matsumoto, Shingo, Goto, Koichi

“…8637 Background: In 2013, a lung cancer genomic screening project (LC-SCRUM-Asia) started in Japan and expanded to other Asia-Pacific countries in October 2022…”
Get full text